Skip to main content
. 2013 Sep 16;5:447–457. doi: 10.2147/CEOR.S46991

Table 3.

Base-case analysis results

Costs per patient (US$) Linezolid (US$) Vancomycin (US$) Daptomycin (US$)
Total inpatient costs $7,835 $7,095 $7,922
 Inpatient drug costs $626 $119 $713
  Drug treatment $554 $47 $659
  Drug administration $72 $72 $54
 Inpatient medical costs $7,209 $6,976 $7,209
  Hospital days $6,068 $6,068 $6,068
  ID specialist $232 $232 $232
  Adverse event costsa $435 $201 $435
  Failure costs $474 $474 $474
Total outpatient costs $2,736 $4,001 $5,690
 Outpatient drug costs $2,086 $634 $2,766
  Drug treatment $2,075 $487 $2,698
  Drug administration $11 $148 $68
 Outpatient medical costs $650 $3,367 $2,924
  Physician visit $246 $246 $246
  Laboratory work $34 $101 $28
  OPAT costb $285 $2,125 $1,840
  PICC line and complicationsb $85 $896 $811
Total cost of treatment $10,571 $11,096 $13,612
 Total drug costs $2,712 $754 $3,479
 Total medical costs $7,859 $10,343 $10,133

Notes: Costs may not tally due to rounding.

a

Adverse event costs are higher for linezolid and daptomycin arm because they are assigned the vancomycin adverse event costs from empiric treatment plus any linezolid/daptomycin adverse event costs. Vancomycin is only assigned adverse event costs once;

b

OPAT and PICC line costs are incurred in the linezolid arm through treatment failures and switching to other IV antibiotics.

Abbreviations: ID, infectious disease; OPAT, outpatient parenteral antibiotic therapy; PICC, peripherally inserted central catheter; IV, intravenous.